cbdMD (YCBD) CEO and CFO granted 445,000 restricted shares, ownership now 513,722

Rhea-AI Filing Summary

cbdMD, Inc. reported an insider equity transaction for its CEO and CFO, who is also a director, on a Form 4. On 11/28/2025, the executive acquired 445,000 shares of common stock as restricted stock. After this grant, the executive beneficially owns 513,722 common shares in total.

The restricted shares were granted under cbdMD’s 2025 Equity Compensation Plan, and the filing notes that the vesting and issuance of these shares are subject to shareholder approval. The company also explains that the current beneficial ownership amount does not reconcile to the prior report because of a scrivener’s error.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kennedy Thomas Ronan

Role CEO and CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	445,000	$0.00	--

Holdings After Transaction: Common Stock — 513,722 shares (Direct)

Footnotes (1)

1. The shares of restricted stock were granted pursuant to the Issuer's 2025 Equity Compensation Plan. The vesting and issuance of the shares is subject to shareholder approval. The amount beneficially owned will not reconcile to the prior Form 4 due to a scriveners error.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kennedy Thomas Ronan

(Last) (First) (Middle)

2101 WESTINGHOUSE BLVD. SUITE A

(Street)

CHARLOTTE NC 28273

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
cbdMD, Inc. [ YCBD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	11/28/2025		A		445,000	A	(1)	513,722(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of restricted stock were granted pursuant to the Issuer's 2025 Equity Compensation Plan. The vesting and issuance of the shares is subject to shareholder approval.

2. The amount beneficially owned will not reconcile to the prior Form 4 due to a scriveners error.

	/s/ T. Ronan Kennedy	12/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did cbdMD (YCBD) report in this Form 4?

The Form 4 reports that cbdMD’s CEO, who is also CFO and a director, acquired 445,000 shares of common stock as restricted stock on 11/28/2025.

How many cbdMD (YCBD) shares does the reporting person now beneficially own?

Following the reported transaction, the executive beneficially owns 513,722 shares of cbdMD common stock.

Under what plan were the cbdMD (YCBD) restricted shares granted?

The restricted shares were granted under cbdMD’s 2025 Equity Compensation Plan, as disclosed in the Form 4 notes.

Are the cbdMD (YCBD) restricted stock shares immediately vested?

No. The filing states that the vesting and issuance of the restricted shares are subject to shareholder approval.

Who is the reporting person in this cbdMD (YCBD) Form 4 and what is their role?

The reporting person is an insider who serves as Director, CEO and CFO of cbdMD, Inc.

Why does the cbdMD (YCBD) beneficial ownership amount differ from a prior report?

The filing explains that the beneficial ownership amount will not reconcile to the prior report due to a scrivener’s error in the earlier filing.